Molecular Partners (NASDAQ:MOLN) Trading 7.1% Higher – Here’s Why

Molecular Partners AG (NASDAQ:MOLN)’s stock price was up 7.1% during mid-day trading on Monday . The company traded as high as $5.44 and last traded at $5.44. 2,138 shares were traded during mid-day trading, a decline of 90% from the average session volume of 22,256 shares. The stock had previously closed at $5.08.

Analyst Ratings Changes

Separately, Leerink Partnrs raised Molecular Partners to a “strong-buy” rating in a research report on Monday, October 7th.

Molecular Partners Price Performance

The company has a fifty day moving average price of $5.67 and a 200 day moving average price of $5.96. The company has a market cap of $214.33 million, a PE ratio of -2.47 and a beta of 1.00.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.